Postbiotics are emerging as a significant new category of microbiome-focused products, offering potential advantages over traditional probiotics through improved stability, simplified manufacturing, and greater formulation flexibility. However, despite growing scientific and commercial interest, regulatory frameworks remain unsettled, with product classification, evidence requirements, and claim substantiation varying across jurisdictions. This article explains what postbiotics are, how they differ from probiotics and prebiotics, why they are attracting industry attention, the regulatory and clinical challenges manufacturers face, and the key scientific considerations for developing credible, compliant products that can successfully navigate evolving food, dietary supplement, and Natural Health Product (NHP) frameworks.
Interest in microbiome-focused products has historically centered on probiotics and, more recently, prebiotics. Increasingly, however, attention is shifting toward a third category: postbiotics.
Unlike probiotics, postbiotics do not rely on the administration of live microorganisms. Instead, they are preparations containing deliberately inactivated microorganisms and/or their components that have been shown to confer a health benefit on the host. These preparations may also contain metabolites generated during fermentation, but purified microbial metabolites alone are not generally considered postbiotics under the widely cited ISAPP definition. This distinction is becoming commercially and scientifically significant as manufacturers look for alternatives that offer improved formulation stability, simplified manufacturing, and the potential to avoid certain risks associated with administering live microorganisms. However, non-viability does not automatically establish safety. The safety of the specific preparation, dose, route of administration and intended population must still be evaluated.
At the same time, the rise of postbiotics is introducing new regulatory and scientific questions. While the term is appearing more frequently across research literature, marketing materials, and product development pipelines, regulatory frameworks have not fully matured around classification, evidence standards, or claim substantiation.
As with earlier phases of the probiotic market, the challenge is no longer simply defining the ingredient category. The more significant issue is determining how these products should be evaluated, characterized, and substantiated within existing food, supplement, and natural health product frameworks.
The most widely cited scientific definition was established by the International Scientific Association for Probiotics and Prebiotics (ISAPP) in 2021. ISAPP defines a postbiotic as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.”
Importantly, not every killed microorganism, bacterial lysate or fermentation-derived substance is automatically a postbiotic. Use of the term implies that the preparation is sufficiently characterized and that a health benefit has been demonstrated in the intended host.
A postbiotic preparation may include:
Purified substances such as short-chain fatty acids, peptides, enzymes, organic acids or extracellular polysaccharides may be microbiome-derived bioactives, but they are not postbiotics on their own if the final preparation does not contain inactivated microbial cells or their components.
This definition distinguishes postbiotics from probiotics, prebiotics and isolated microbial metabolites:
Microbial metabolites are substances produced by microorganisms. They may be present in a postbiotic preparation, but isolated metabolites are not necessarily postbiotics. This distinction has major implications for product development and regulatory oversight.
Part of the interest surrounding postbiotics stems from the operational challenges associated with live microorganisms.
Traditional probiotic products require manufacturers to maintain microbial viability throughout manufacturing, storage, transportation, and shelf life. Stability can be affected by temperature, moisture, oxygen exposure, formulation matrix, and packaging conditions.
Postbiotics avoid the requirement to maintain a specified population of viable microorganisms throughout shelf life. This can reduce certain stability and distribution constraints, although the manufacturer must still demonstrate that the inactivation process, composition and biological activity of the preparation remain controlled and reproducible. From a formulation perspective, this creates several practical advantages:
These advantages are preparation-specific. Heat, pressure, irradiation or other inactivation methods can produce different cellular structures and biological activities, even when the same microorganism is used. Evidence generated using one manufacturing process may therefore not apply to a materially different preparation.
Because postbiotics do not contain intentionally viable microorganisms, they may avoid certain concerns associated with microbial replication or translocation. This has generated interest in their potential use where administration of live microorganisms may warrant additional caution.
However, suitability for immunocompromised individuals, neonates or other vulnerable populations must be established using evidence for the specific preparation and intended use. Inactivation does not, by itself, establish that a product is safe for these populations.
At the same time, commercial interest is being driven by broader consumer trends around gut health, immune support, and microbiome-targeted products.
The rapid expansion of terminology within the microbiome category is creating increasing complexity for both industry and regulators.
Consumers are now exposed to overlapping concepts including:
Scientifically, these categories are not interchangeable. However, marketing language often blurs the distinctions between them.
This is particularly important from a regulatory perspective because classification, evidence requirements, and permissible claims may differ substantially depending on how a product is positioned.
Dicentra’s previous review of prebiotic versus probiotic claims highlighted that regulators increasingly expect companies to distinguish between direct microbial effects, substrate-mediated effects, and generalized digestive health claims.
Postbiotics add another layer to this discussion because they may derive from microbial fermentation without containing viable organisms themselves.
As a result, regulators may increasingly focus on questions such as:
These are questions that extend beyond microbiology alone and move directly into regulatory characterization and substantiation.
One of the most important realities facing the postbiotic market is that regulatory frameworks remain less developed than they are for probiotics.
“Postbiotic” is primarily a scientific and commercial descriptor rather than a harmonized legal product category. Regulatory status must therefore be determined under the existing framework of each jurisdiction. Instead, classification depends on several existing factors, including:
Depending on the jurisdiction, ingredient, product format, intended use and claims, a product may be regulated as:
“Functional food” may be useful as a commercial description, but it is not a distinct legal category in every jurisdiction.
For example, a Canadian product may require assessment under the food, Natural Health Product or drug framework depending on its composition, presentation and claims. In the United States, food use may require an appropriate food-ingredient basis, while supplement use may raise dietary-ingredient and New Dietary Ingredient considerations. In the European Union, novel food status and the permissibility of health-related claims may both require assessment.
This creates important strategic considerations for manufacturers, particularly where products move beyond generalized wellness positioning into more targeted physiological or therapeutic claims.
As regulators continue refining microbiome-related frameworks, one likely area of focus will be evidentiary specificity.
The probiotic sector has already established that health effects are often strain-specific and cannot automatically be generalized across related organisms. Postbiotics may face similar scrutiny regarding:
For postbiotics, evidence may need to be linked not only to the source organism but also to the specific inactivation method, manufacturing conditions, final composition and dose. A study conducted using one preparation may not substantiate another product simply because both originated from the same microbial strain.
This is especially relevant because postbiotics are not single substances, but often complex mixtures of metabolites and cellular components generated through fermentation processes.
One of the recurring themes across the postbiotic literature is that scientific enthusiasm currently exceeds regulatory consensus.
Candidate postbiotic preparations have been investigated for potential physiological effects involving:
The strength of evidence differs substantially by preparation, indication and population. In vitro activity, animal findings and changes in mechanistic biomarkers should not be presented as equivalent to demonstrated, clinically meaningful benefits in humans.
However, many proposed mechanisms remain incompletely characterized. Several review articles note that although postbiotic research is expanding rapidly, mechanistic clarity and standardized definitions remain limited.
From a regulatory standpoint, this matters because claim substantiation ultimately depends on demonstrating that:
A fully established mechanism of action may not always be required for a permitted food or supplement claim. However, mechanistic evidence can strengthen biological plausibility and help establish whether the marketed preparation is comparable to the preparation used in supporting studies.
As the category matures, manufacturers will likely face increasing pressure to move beyond generalized microbiome narratives toward more precisely characterized evidence packages.
Although postbiotics avoid some of the viability challenges associated with probiotics, they do not eliminate the need for rigorous clinical strategy.
In many respects, existing probiotic clinical principles remain highly relevant.
For example:
This comparability question may be particularly important for postbiotics because changing the inactivation method or downstream processing conditions can change the resulting preparation. Clinical evidence cannot necessarily be transferred to a reformulated or differently manufactured product without scientific justification.
dicentra’s previous analysis of probiotic endpoint selection emphasized that microbiome-related studies frequently fail not because the intervention lacks activity, but because endpoints are poorly aligned with the intended claim or regulatory positioning.
That same principle applies to postbiotics.
Similarly, considerations around placebo design, formulation comparability, and blinding remain important where sensory or physiological effects may influence study outcomes.
As the category evolves, postbiotic clinical development will likely require increasingly sophisticated study designs capable of balancing mechanistic science with clinically meaningful endpoints.
The emergence of postbiotics reflects a broader transition occurring across the microbiome sector.
Early probiotic development focused heavily on introducing beneficial live organisms. More recent research increasingly examines how inactivated microorganisms, cellular structures and microbially derived compounds interact with host biological pathways. These areas overlap, but they should not all be described as postbiotics unless the resulting preparation meets the applicable scientific definition.
This shift has important commercial implications.
Postbiotics may offer manufacturers opportunities to:
These benefits must be balanced against the need to validate inactivation, define the active preparation, control batch-to-batch variability and demonstrate that processing does not materially alter the clinically supported product.
At the same time, the category introduces new scientific and regulatory complexity around characterization, substantiation, and classification.
As with many emerging health product categories, the companies most likely to succeed will not necessarily be those moving fastest, but those building the strongest scientific and regulatory foundations early.
At dicentra, we support companies navigating the evolving regulatory and clinical landscape surrounding microbiome-related products, including probiotics, prebiotics, synbiotics, and postbiotics.
As the postbiotic category continues to develop, manufacturers are increasingly facing questions around classification, claim substantiation, clinical strategy, and product characterization.
We support organizations by:
Our role is to help organizations bring microbiome-focused products to market with a regulatory and scientific strategy that remains credible, defensible, and commercially aligned.
Contact dicentra for support with postbiotic regulatory strategy, clinical development, and microbiome product compliance.